Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Laxman 7-marker panel for prostate cancer

Laxman 7-marker panel for prostate cancer



QA State: Curated
Short Name:
HGNC Name:

This 7-marker multiplex panel of urine transcripts outperforms PCA3 transcript alone for the detection of prostate cancer. The panel consists of PCA3, AMACR, ERG, GP73 (GOLPH2), SPINK1, TFF3, and TMPRSS2:ERG fusion.

Panel Details


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


This 7-marker panel has been shown to outperform serum PSA or PCA3 assays alone when used on sedimented urine from patients considered for prostate biopsy or prostatectomy.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated publications found.


No associated resources found.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.